ARV7, an aberrantly spliced mRNA isoform of the androgen receptor, has been proved by increasing evidences that ARV7 mRNA abstracted from circulating tumor cells (CTCs) may be a prognostic marker which can both indicate the resistance against novel endocrine therapies, including abiraterone and enzalutamide (44) and play a role in the prediction of sensitivity toward chemotherapeutic, such as docetaxel and cabazitaxel (45, 46). Here, AR is linked to neoplasm.